CompareRecursionvsIsomorphic Labs

Recursion is an AI drug discovery company that uses cellular imaging, automation, and machine learning to identify and validate new drug candidates. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.

The clearest fit for Recursion is pharma collaborators and internal pipeline programs, with the platform leaning into phenomics platform with multimodal data. Limitations are real: direct buyer access is limited to partnerships. Pricing is sales-led and scoped per buyer rather than posted publicly. Buyers should confirm validation depth, support coverage, and rollout plan before signing.

Isomorphic Labs is a DeepMind spinout building AI models for drug design, including protein structure prediction and molecule generation for pharma partners. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.

For large pharma partners and biologics programs, Isomorphic Labs is worth a serious look thanks to frontier ai models for biologics design. The honest trade-off is that not a self-serve buyer product today. Pricing is sales-led and scoped per buyer rather than posted publicly. Buyers should still verify EHR or workflow fit, scope, and support before committing.